| 124978 |
ONCOIMMUNOLOGY |
Interferon α may be back on track to treat acute myeloid leukemia. |
2013-04-01 |
10.4161/onci.23619 |
Smits Evelien L.J.M., Anguille Sébastien, Berneman Zwi N. |
| 124977 |
ONCOIMMUNOLOGY |
Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands. |
2013-04-01 |
10.4161/onci.23493 |
Chew Valerie, Abastado Jean-Pierre |
| 124976 |
ONCOIMMUNOLOGY |
Toll-like receptor 5 and the emerging role of bacteria in carcinogenesis. |
2013-04-01 |
10.4161/onci.23620 |
Kauppila Joonas H., Mattila Antti E., Karttunen Tuomo J., Salo Tuula |
| 124975 |
ONCOIMMUNOLOGY |
The RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis |
2013-04-01 |
10.4161/onci.23566 |
Kaneda Yasufumi |
| 124974 |
ONCOIMMUNOLOGY |
Toward the next generation of NK cell-based adoptive cancer immunotherapy. |
2013-04-01 |
10.4161/onci.23811 |
Ni Jing, Miller Matthias, Stojanovic Ana, Cerwenka Adelheid |
| 124973 |
ONCOIMMUNOLOGY |
Mimotope vaccine efficacy gets a "boost" from native tumor antigens. |
2013-04-01 |
10.4161/onci.23492 |
Buhrman Jonathan D., Slansky Jill E. |
| 124972 |
ONCOTARGETS AND THERAPY |
HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients |
2013-04-01 |
10.2147/ott.s40851 |
Qin Tao, Yuan, Peng, Bai, Shi, Teng, Liu, Wang |
| 124971 |
ONCOIMMUNOLOGY |
Glycan-mediated modification of the immune response |
2013-04-01 |
10.4161/onci.23659 |
Madsen Caroline B., Pedersen Anders E., Wandall Hans H. |
| 124970 |
ONCOIMMUNOLOGY |
Myeloid derived suppressor cells : Targets for therapy |
2013-04-01 |
10.4161/onci.24117 |
Waldron Todd J., Quatromoni Jon G., Karakasheva Tatiana A., Singhal Sunil, Rustgi Anil K. |
| 124969 |
ONCOIMMUNOLOGY |
Cancer immunotherapy turns viral. |
2013-04-01 |
10.4161/onci.24802 |
Galluzzi Lorenzo, Lugli Enrico |
